drugset
Drugs / NMRC-M3V-Ad-PfCA
last change Sep 2017 re-read 3 minutes ago

NMRC-M3V-Ad-PfCA

Vaccine

Developed for
Plasmodium falciparum malaria
Investigated by
Congressionally Directed Medical Research Programs · Military Infectious Diseases Research Program (MIDRP) · Naval Medical Research Center · U.S. Army Medical Research and Development Command · United States Agency for International Development (USAID)

Trials 1

today NCT00392015 · Ph 1/2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00392015 Oct 2006 → Jun 2016 Plasmodium falciparum malaria U.S. Army Medical Research and Development Command Completed Missed primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NMRC-M3V-Ad-PfCA ClinicalTrials.gov intervention name — accepted as the source's own label NCT00392015 ↗
Modality Vaccine “a multivalent, adenovirus-vectored Plasmodium Falciparum Malaria Vaccine” NCT00392015 ↗
Route Intramuscular “administered intramuscularly” NCT00392015 ↗